Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI

Cancer Research

Volumn 74, Issue 3, 2014, Pages 686-694

  Mignion, Lionel ^a   Dutta, Prasanta ^b   Martinez, Gary V ^b   Foroutan, Parastou ^b   Gillies, Robert J ^b   Jordan, Benedicte F ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON ISOTOPES; CELL LINE, TUMOR; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE MODELS, ANIMAL; FEMALE; FUMARATES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893837433     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1914     Document Type: Article

References (50)

1. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010;16:3329-34.
2. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
3. WilhelmSM, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev Cancer 2006;5:835-44.
4. Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, et al. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 2011;13:1324-30.
5. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84.
6. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30.
7. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JWA, Reike G, et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349.
8. Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS ONE 2010;5:e15588.
9. Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL III, Othus M, et al. Randomized phase II trial of sorafenib with temsirolimus or Tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res 2012;18:1129-37.
10. Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin Y-M, Chevreau C, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist 2012;17:260-6.
11. Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010;28:3330-35.
12. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011;96:62-68.
13. von Mehren M, Rankin C, GoldblumJR, Demetri GD, Bramwell V, Ryan CW, et al. Phase IISWOG-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 2012;118:770-6.
14. Koh D-M, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJRAmJ Roentgenol 2007;188:1622-35.
15. Morse DL, Galons J-P, Payne CM, Jennings DL, Day S, Xia G, et al. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed 2007;20:602-14.
16. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007;25:4104-109.
17. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magnetic Resonance in Medicine 2000; 43:828-36.
18. Lodi A, Woods SM, Ronen SM. Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells. NMR Biomed. 2013;26: 299-306
19. Beloueche-Babari M, Chung Y-L, Al-Saffar NMS, Falck-Miniotis M, Leach MO. Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br J Cancer 2010;102:1-7.
20. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH. Increase in signal-to-noise ratio of >10,000 times in liquidstate NMR. Proc Natl Acad Sci U S A 2003;100:10158-10163.
21. Bohndiek SE, Kettunen MI, Hu D, Kennedy BWC, Boren J, Gallagher FA, et al. Hyperpolarized [1-13C]-ascorbic and dehydroascorbic acid: vitamin C as a probe for imaging redox status in vivo. J Am Chem Soc 2011;133:11795-801.
22. Nelson SJ, Vigneron D, Kurhanewicz J, Chen A, Bok R, Hurd R. DNPhyperpolarized 13C magnetic resonance metabolic imaging for cancer applications. Appl Magn Reson 2008;34:533-44.
23. Kurhanewicz J, Vigneron DB, Brindle K, Chekmenev EY, Comment A, Cunningham CH, et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 2011;13:81-97.
24. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson P, Harzstarck A, Ferrone M, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C] pyruvate. Sci Tran Medi 2013;5: 198ra108.
25. Gallagher FA, Kettunen MI, Hu D-E, Jensen PR, Zandt RI, Karlsson M, et al. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci U S A 2009;106:19801-6.
26. Brindle KM, Bohndiek SE, Gallagher FA, Kettunen MI. Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopy. Magn Reson Med 2011;66:505-19.
27. Witney TH, Kettunen MI, Hu D, Gallagher FA, Bohndiek SE, Napolitano R, et al. Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate. Br J Cancer 2010;103:1400-6.
28. Bohndiek SE, Kettunen MI, Hu D, Witney TH, Kennedy BWC, Gallagher FA, et al. Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy. Mol Cancer Ther 2010;9:3278-88.
29. Mallet RT. Pyruvate: metabolic protector of cardiac performance. Proc Soc Exp Biol Med 2000;223:136-48.
30. Park I, Larson PEZ, Zierhut ML, Hu S, Bok R, Ozawa T, et al. Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol 2010;12:133-44.
31. Golman K, Zandt RI, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006;66:10855-60.
32. Day SE, Kettunen MI, Gallagher FA, Hu D-E, Lerche M, Wolber J, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 2007;13: 1382-7.
33. Dafni H, Larson PEZ, Hu S, Yoshihara HAI, Ward CS, Venkatesh HS, et al. Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer Res 2010;70:7400-10.
34. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res 2010;70:1296-1305.
35. Day SE, Kettunen MI, Cherukuri MK, Mitchell JB, Lizak MJ, Morris HD, et al. Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1-13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn Reson Med 2011;65:557-63.
36. Dutta P, Le A, Vander Jagt DL, Tsukamoto T, Martinez GV, Dang CV, et al. Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. Cancer Res 2013;73:4190-5.
37. Mulrane L, Rexhepaj E, Penney S, Callanan JJ, Gallagher WM. Automated image analyses in histopathology: a valuable toll in medical diagnostics. Expert Rev Mol Diagn 2008;8:707-25
38. Brindle K. New approaches for imaging tumour responses to treatment. Nat. Rev. Cancer 2008;8:94-107.
39. Milano A, Perri F, Ciarmiello A, Caponigro F. Targeted-therapy and imaging response: a new paradigm for clinical evaluation? Rev Recent Clin Trials 2011;6:259-65.
40. Abou-Alfa GK, Schwartz L, Ricci S,Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
41. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-92S.
42. Flaherty KT, Brose M, Schuchter LM, Tuveson D, Lee R, Schwartz B, et al. Phase I/II trial of BAY 43-9006, carboplatin, and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 2004;22:14S (abstr 7507).
43. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol 2004;22:14S (abstr 4501).
44. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 2000;27:683-7.
45. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16: 407-22.
46. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-52.
47. Bohndiek SE, Kettunen MI, Hu DE, Brindle KM. Hyperpolarized 13C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization. Cancer Res 2012;72:854-64.
48. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJS, Bentzen S, Stirling JJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semiquantitative analysis. NMR Biomed 2002;15:132-42.
49. Harris T, Eliyahu G, Frydman L, Degani H. Kinetics of hyperpolarized 13C1-pyruvate transport and metabolism in living human breast cancer cells. Proc Natl Acad Sci U S A 2009;106:18131-6.
50. Wang Q, Morris ME. The role of monocarboxylate transporter 2 and 4 in the transport of gamma-hydroxybutyric acid in mammalian cells. Drug Metab Dispos 2007;35:1393-9.